SUPN: Supernus Pharmaceuticals, Inc. Net Sales Margin

Supernus Pharmaceuticals (SUPN) leads in the therapy of epilepsy and ADHD, expanding its reach across the global neurology market. The company maintains a flawless reputation among specialists thanks to its science-based innovations. Analyzing the chart on GURU.Markets, we find that the net margin trend reflects a current value of 32.80. The risks associated with a narrow focus on the CNS are mitigated by a strategic portfolio allocation across various drug classes.
Analytical breakdowns and data insights for company Supernus Pharma (SUPN)

Net margin reflects the portion of final profit in every dollar of revenue after covering all operating and tax expenses, serving as a measure of efficiency in transforming revenue into capital. Analysis of the net margin allows for the filtering of random spikes, confirming the ability of Supernus Pharmaceuticals (SUPN) to generate excess profits through pricing power and the low impact of Capex on scaling drug production.